SCHEMBL19743587

SCHEMBL19743587

CN(Cc1ccccc1)c1cccc(OCCNC(=O)O)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 1/20 0.47
USP30 Q70CQ3 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
CASR P41180 5/20 0.41
LOXL2 Q9Y4K0 1/20 0.39
KLKB1 P03952 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.39
KCNH2 Q12809 1/20 0.39
RPS6KB1 P23443 1/20 0.38
HDAC1 Q13547 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
MTNR1A P48039 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19743711 0.85 HTR1A (0.44) L3MBTL1MAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL19743650 0.82 ALDH1A1 (0.42) MAP2K7L3MBTL1CASRMAPTKMT2A
SCHEMBL19743714 0.80 ALDH1A1 (0.46) L3MBTL1CASRMAPTSMN1; SMN2KCNH2
Hydrochloric Acid SCHEMBL19744011 0.79 SMN1; SMN2 (0.43) MAP2K7LOXL2MAPTTSHRKMT2A
SCHEMBL21383930 0.76 MTNR1A (0.44) L3MBTL1MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL19743601 0.72 HTR1A (0.43) L3MBTL1MAPTKMT2ASMN1; SMN2KDM4E
SCHEMBL16061881 0.72 HTR7 (0.51) L3MBTL1MAPTSMN1; SMN2KDM4EALDH1A1
SCHEMBL25226515 0.72 TRPV3 (0.43)
SCHEMBL25271903 0.71 MAOB (0.44) L3MBTL1TSHRALDH1A1HPGD
SCHEMBL25224130 0.71 ALDH1A1 (0.46) L3MBTL1TSHRKMT2ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3475268-B9 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2021-04-21 EP disclosed
EP-3475268-B1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2020-08-19 EP disclosed
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors NEUROLIXIS (FR) 2020-02-18 US disclosed
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2019-06-27 US disclosed
EP-3475268-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS Neurolixis (FR) 2019-05-01 EP disclosed
WO-2017220799-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS NEUROLIXIS (FR) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562853-B2 Compounds for treating disorders sensitive to serotoninergic regulation controlled by the 5-HT1A receptors HTR5A, HTR1A, HTR1E MAP2K7 490/4885USP30 1883/4885L3MBTL1 1802/4885
US-20190194132-A1 COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS HTR5A, HTR1A, HTR1E MAP2K7 490/4885USP30 1883/4885L3MBTL1 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.